26 May 2015

Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias

Video of Prof Elsdon Storey describing his centre's research
including Parkinson's Disorder
Effective treatment for Parkinson's Disorder (PD) patients remains elusive. While Levadopa (l-dopa) is the most widely used antiparkinsonian medication, it also can induce dyskinesias, or movement disorders. This is the largest ever study to examine pathological changes in a post-mortem PD cohort specifically separated according their dyskinetic phenotype, thereby allowing a direct correlation of biochemical markers with l-dopa–induced dyskinesias (LID) incidence and severity. 

Reference: Cheshire P, Ayton S, Bertram KL, Ling H, Li A, McLean C, Halliday GM, O'Sullivan SS, Revesz T, Finkelstein DL, Storey E, Williams DR. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Mov Disord. 2015 May;30(6):796-804. doi: 10.1002/mds.26144

No comments:

Post a Comment

Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.

Related Posts Plugin for WordPress, Blogger...